Literature DB >> 22762561

Liver transplant outcomes in HIV+ haemophilic men.

M V Ragni1, M E Devera, M E Roland, M Wong, V Stosor, K E Sherman, D Hardy, E Blumberg, J Fung, B Barin, D Stablein, P G Stock.   

Abstract

Hepatitis C virus infection is the major cause of end-stage liver disease and the major indication for transplantation (OLTX), including among HIV-HCV co-infected individuals. The age of HCV acquisition differs between haemophilic and non-haemophilic candidates, which may affect liver disease outcomes. The purpose of the study was to compare rates of pre- and post-OLTX mortality between co-infected haemophilic and non-haemophilic subjects without hepatocellular cancer participating in the Solid Organ Transplantation in HIV Study (HIV-TR). Clinical variables included age, gender, race, liver disease aetiology, BMI, antiretroviral therapy, MELD score, CD4 + cell count, HIV RNA PCR and HCV RNA PCR. Time to transplant, rejection and death were determined. Of 104 HIV-HCV positive subjects enrolled, 34 (32.7%) underwent liver transplantation, including 7 of 15 (46.7%) haemophilic and 27 of 89 (30.3%) non-haemophilic candidates. Although haemophilic subjects were younger, median 41 vs. 47 years, P = 0.01, they were more likely than non-haemophilic subjects to die pre-OLTX, 5 (33.3%) vs. 13 (14.6%), P = 0.03, and reached MELD = 25 marginally faster, 0.01 vs. 0.7 years, P = 0.06. The groups did not differ in baseline BMI, CD4, detectable HIV RNA, detectable HCV RNA, time to post-OLTX death (P = 0.64), graft loss (P = 0.80), or treated rejection (P = 0.77). The rate of rejection was 14% vs. 36% at 1-year and 36% vs. 43% at 3-year, haemophilic vs. non-haemophilic subjects, respectively, and post-OLTX survival, 71% vs. 66% at 1-year and 38% vs. 53% at 3-year. Despite similar transplant outcomes, pretransplant mortality is higher among co-infected haemophilic than non-haemophilic candidates.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22762561      PMCID: PMC4351753          DOI: 10.1111/j.1365-2516.2012.02905.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  27 in total

1.  Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

Authors:  Norbert Bräu; Mirella Salvatore; Carlos F Ríos-Bedoya; Alberto Fernández-Carbia; Fiorenzo Paronetto; José F Rodríguez-Orengo; Maribel Rodríguez-Torres
Journal:  J Hepatol       Date:  2005-07-27       Impact factor: 25.083

2.  Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.

Authors:  M E de Vera; I Dvorchik; K Tom; B Eghtesad; N Thai; O Shakil; A Marcos; A Demetris; A Jain; J J Fung; M V Ragni
Journal:  Am J Transplant       Date:  2006-12       Impact factor: 8.086

3.  Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.

Authors:  A Mocroft; A N Phillips; V Soriano; J Rockstroh; A Blaxhult; C Katlama; A Boron-Kaczmarska; L Viksna; O Kirk; J D Lundgren
Journal:  AIDS Res Hum Retroviruses       Date:  2005-09       Impact factor: 2.205

4.  Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages.

Authors:  Shuzhen Chen; Daniel L Tuttle; Joseph T Oshier; Harm J Knot; Wolfgang J Streit; Maureen M Goodenow; Jeffrey K Harrison
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

5.  HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

Authors:  Juan A Pineda; Manuel Romero-Gómez; Fernando Díaz-García; José A Girón-González; José L Montero; Julián Torre-Cisneros; Raúl J Andrade; Mercedes González-Serrano; José Aguilar; Manuela Aguilar-Guisado; José M Navarro; Javier Salmerón; Francisco J Caballero-Granado; José A García-García
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

Review 6.  Liver transplantation in HIV-infected recipients.

Authors:  Michelle E Roland; Peter G Stock
Journal:  Semin Liver Dis       Date:  2006-08       Impact factor: 6.115

7.  Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.

Authors:  Margaret V Ragni; Bijan Eghtesad; Kimberly W Schlesinger; Igor Dvorchik; John J Fung
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

8.  Suppression of hepatitis C virus replicon by TGF-beta.

Authors:  Takayuki Murata; Takayuki Ohshima; Masashi Yamaji; Masahiro Hosaka; Yusuke Miyanari; Makoto Hijikata; Kunitada Shimotohno
Journal:  Virology       Date:  2005-01-20       Impact factor: 3.616

9.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

Review 10.  Liver transplantation in HIV/hepatitis co-infection.

Authors:  Jose M Miro; Fernando Aguero; Montserrat Laguno; Montserrat Tuset; Carlos Cervera; Asuncion Moreno; Juan-Carlos Garcia-Valdecasas; Antonio Rimola
Journal:  J HIV Ther       Date:  2007-03
View more
  3 in total

1.  Hemophilia Liver Transplantation Observational Study.

Authors:  Margaret V Ragni; Abhinav Humar; Peter G Stock; Emily A Blumberg; Bijan Eghtesad; John J Fung; Valentina Stosor; Nicholas Nissen; Michael T Wong; Kenneth E Sherman; Donald M Stablein; Burc Barin
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

2.  Organ Transplantation in HIV Patients: Current Status and New Directions.

Authors:  Valentina Stosor
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 3.  Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.

Authors:  Rebecca N Kumar; Valentina Stosor
Journal:  Curr Infect Dis Rep       Date:  2022-03-15       Impact factor: 3.663

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.